Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Cell Cycle ; 9(16): 3297-304, 2010 Aug 15.
Article in English | MEDLINE | ID: mdl-20703093

ABSTRACT

The role of JAK signaling in cell cycle transit and maintenance of genomic stability was determined in HL-60 human myeloblastic leukemia cells. We have previously reported that a pan-JAK inhibitor caused ERK-dependent endoreduplication. In the current study we find that JAK inhibition caused nuclear re-localization of RAF-1 which could be inhibited by RAF inhibitor GW5074. GW5074 also inhibited JAK inhibitor-induced appearance of nuclear phosphorylated RAF-1(pS621RAF) and MEK; and it inhibited the JAK inhibitor-induced co-immunoprecipitation of nuclear RAF-1 and MEK. JAK inhibition also increased nuclear BubR1 phosphorylation, which was diminished by RAF inhibitor GW5074. RAF-1 and BubR1 in the nucleus co-immunoprecipitated; and GW5074 eliminated this. Furthermore, inhibiting RAF with GW5074 blocked the pan-JAK inhibitor-induced endoreduplication. These data thus show that JAK inhibition causes nuclear relocalization and phosphorylation of RAF and MEK where RAF binds BubR1 with ensuing nuclear RAF-dependent BubR1 phosphorylation. Inhibiting RAF inhibited this and endoreduplication. The results suggest that there is a JAK/RAF/MEK/BubR1 axis that can regulate genomic stability. In this hypothetical model JAK suppresses RAF/MEK phosphorylation and nuclear re-localization, but JAK inhibition induces the phosphorylations and relocalization with association of RAF and phosphorylated BubR1 in the nucleus leading to endoreduplication.


Subject(s)
Janus Kinases/antagonists & inhibitors , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins c-raf/metabolism , Cell Nucleus/metabolism , Genomic Instability , HL-60 Cells , Humans , Indoles/pharmacology , Janus Kinases/metabolism , MAP Kinase Kinase 1/metabolism , Mitosis , Phenols/pharmacology , Phosphorylation , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins c-raf/antagonists & inhibitors , Signal Transduction , Time Factors
2.
Exp Cell Res ; 315(13): 2241-8, 2009 Aug 01.
Article in English | MEDLINE | ID: mdl-19298812

ABSTRACT

All trans-retinoic acid (RA) is a standard therapeutic agent used in differentiation induction therapy treatment of acute promyelocytic leukemia (APL). RA and its metabolites use a diverse set of signal transduction pathways during the differentiation program. In addition to the direct transcriptional targets of the nuclear RAR and RXR receptors, signals derived from membrane receptors and the Raf-MEK-ERK pathway are required. Raf1 phosphorylation and the prolonged activation of Raf1 persisting during the entire differentiation process are required for RA-dependent differentiation of HL-60 cells. Here we identify a nuclear redistribution of Raf1 during the RA-induced differentiation of HL-60 cells. In addition, the nuclear accumulation of Raf1 correlates with an increase in Raf1 phosphorylated at serine 621. The serine 621 phosphorylated Raf1 is predominantly localized in the nucleus. The RA-dependent nuclear accumulation of Raf1 suggests a novel nuclear role for Raf1 during the differentiation process.


Subject(s)
Antineoplastic Agents/pharmacology , Cell Differentiation/physiology , Cell Nucleus/metabolism , HL-60 Cells/drug effects , Proto-Oncogene Proteins c-raf/metabolism , Tretinoin/pharmacology , Animals , Anthraquinones/metabolism , Bone Marrow Cells/cytology , Bone Marrow Cells/physiology , Humans , Mice , Mice, Inbred C57BL , Phosphorylation , Proto-Oncogene Proteins c-raf/genetics , Serine/metabolism
3.
Exp Cell Res ; 314(16): 2999-3006, 2008 Oct 01.
Article in English | MEDLINE | ID: mdl-18692045

ABSTRACT

Estrogen receptors are historically perceived as nuclear ligand activated transcription factors. An estrogen receptor has now been found localized to the plasma membrane of human myeloblastic leukemia cells (HL-60). Its expression occurs throughout the cell cycle, progressively increasing as cells mature from G(1) to S to G(2)/M. To ascertain that the receptor functioned, the effect of ligands, including a non-internalizable estradiol-BSA conjugate and tamoxifen, an antagonist of nuclear estrogen receptor function, were tested. The ligands caused activation of the ERK MAPK pathway. They also modulated the effect of retinoic acid, an inducer of MAPK dependent terminal differentiation along the myeloid lineage in these cells. In particular the ligands inhibited retinoic acid-induced inducible oxidative metabolism, a functional marker of terminal myeloid cell differentiation. To a lesser degree they also diminished retinoic acid-induced earlier markers of cell differentiation, namely CD38 and CD11b. However, they did not regulate retinoic acid-induced G(0) cell cycle arrest. There is thus a membrane localized estrogen receptor in HL-60 myeloblastic leukemia cells that can cause ERK activation and modulates the response of these cells to retinoic acid, indicating crosstalk between the membrane estrogen and retinoic acid evoked pathways relevant to propulsion of cell differentiation.


Subject(s)
Cell Differentiation/drug effects , HL-60 Cells , Receptors, Estrogen/metabolism , Tretinoin/pharmacology , ADP-ribosyl Cyclase 1/genetics , ADP-ribosyl Cyclase 1/metabolism , CD11b Antigen/genetics , CD11b Antigen/metabolism , Cell Cycle/physiology , Cell Membrane/metabolism , Enzyme Activation , Estrogen Antagonists/metabolism , Estrogens/metabolism , Extracellular Signal-Regulated MAP Kinases/genetics , Extracellular Signal-Regulated MAP Kinases/metabolism , HL-60 Cells/drug effects , HL-60 Cells/metabolism , Humans , Membrane Glycoproteins/genetics , Membrane Glycoproteins/metabolism , Reactive Oxygen Species/metabolism , Receptors, Estrogen/genetics , Signal Transduction/physiology , Tamoxifen/metabolism
4.
FEBS Lett ; 582(17): 2508-14, 2008 Jul 23.
Article in English | MEDLINE | ID: mdl-18571505

ABSTRACT

PDGFR inhibitors are successfully used in a number of cancer treatments. The standard treatment for acute promyelocytic leukemia (APL) involves differentiation therapy with retinoic acid (RA). However, the relapse rates are significant. In the present work we evaluated the effects of RA therapy in the presence of PDGFR inhibitor, AG1296. Adding AG1296 with RA increased secretion of TNF-alpha, IL-8, and MMP-9 expression. This treatment induced higher levels of ICAM-1 endothelial cell expression, and increased cellular mobility. Inhibiting PDGFR enhanced RA-induced expression of integrin. Integrin ligand increased differentiation markers CD11b, inducible oxidative metabolism and PDGFR-beta phosphorylation. While the neutrophil-endothelial cell interactions are strengthened by the combined treatment, the endothelium-substratum interactions are weakened, a situation common in RAS.


Subject(s)
Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols , Drug Resistance, Neoplasm , Leukemia, Promyelocytic, Acute/drug therapy , Protein Kinase Inhibitors , Receptors, Platelet-Derived Growth Factor/antagonists & inhibitors , Tretinoin/therapeutic use , Tyrphostins , CD18 Antigens/metabolism , Cell Differentiation , Cell Movement/drug effects , Contraindications , Endothelial Cells/drug effects , Endothelial Cells/metabolism , HL-60 Cells , Humans , Intercellular Adhesion Molecule-1/metabolism , Interleukin-8/metabolism , Leukemia, Promyelocytic, Acute/pathology , Ligands , Macrophage-1 Antigen/metabolism , Matrix Metalloproteinase 9/metabolism , Protein Kinase Inhibitors/therapeutic use , Receptor, Platelet-Derived Growth Factor beta/antagonists & inhibitors , Receptor, Platelet-Derived Growth Factor beta/metabolism , Receptors, Platelet-Derived Growth Factor/metabolism , Syndrome , Tumor Necrosis Factor-alpha/metabolism , Tyrphostins/therapeutic use
5.
Chem Biol Interact ; 172(1): 27-38, 2008 Mar 10.
Article in English | MEDLINE | ID: mdl-18155686

ABSTRACT

Exposure to persistent organic pollutants, such as polychlorinated biphenyls (PCBs) can cause endothelial cell (EC) activation by inducing pro-inflammatory signaling pathways. Our previous studies indicated that linoleic acid (LA, 18:2), a major omega-6 unsaturated fatty acid in the American diet, can potentiate PCB77-mediated inflammatory responses in EC. In addition, omega-3 fatty acids (such as alpha-linolenic acid, ALA and 18:3) are known for their anti-inflammatory properties. We tested the hypothesis that mechanisms of PCB-induced endothelial cell activation and inflammation can be modified by different ratios of omega-6 to omega-3 fatty acids. EC were pretreated with LA, ALA, or different ratios of these fatty acids, followed by exposure to PCB77. PCB77-induced oxidative stress and activation of the oxidative stress sensitive transcription factor nuclear factor kappaB (NF-kappaB) were markedly increased in the presence of LA and diminished by increasing the relative amount of ALA to LA. Similar protective effects by increasing ALA were observed by measuring NF-kappaB-responsive genes, such as vascular cell adhesion molecule-1 (VCAM-1) and cyclooxygenase-2 (COX-2). COX-2 catalyzes the rate limiting step of the biosynthesis of prostaglandin E(2) (PGE(2)). PCB77 exposure also increased PGE(2) levels, which were down-regulated with relative increasing amounts of ALA to LA. The present studies suggest that NF-kappaB is a critical player in the regulation of PCB-induced inflammatory markers as modulated by omega-6 and omega-3 fatty acids.


Subject(s)
Endothelial Cells/drug effects , Endothelial Cells/pathology , Fatty Acids, Omega-3/pharmacology , Fatty Acids, Omega-6/pharmacology , Polychlorinated Biphenyls/toxicity , Animals , Anti-Inflammatory Agents/pharmacology , Cells, Cultured , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Dinoprostone/biosynthesis , Gene Expression Regulation/drug effects , Inflammation , Linoleic Acid/pharmacology , NF-kappa B/antagonists & inhibitors , Pulmonary Artery/cytology , Swine , Vascular Cell Adhesion Molecule-1/genetics , Vascular Cell Adhesion Molecule-1/metabolism
6.
Cardiovasc Toxicol ; 7(4): 264-72, 2007.
Article in English | MEDLINE | ID: mdl-17955387

ABSTRACT

Exposure to polychlorinated biphenyls (PCBs) can activate inflammatory responses in vascular endothelial cells. Activation of peroxisome proliferator-activated receptors (PPARs) by nutrients or synthetic agonists has been shown to block pro-inflammatory responses both in vitro and in vivo. Here we demonstrate that activation of PPARalpha by synthetic agonists can reduce 3,3'4,4'-tetrachlorobiphenyl (PCB77)-induced endothelial cell activation. Primary vascular endothelial cells were pretreated with the PPARalpha ligands fenofibrate or WY14643 followed by exposure to PCB77. PPARalpha activation protected endothelial cells against PCB77-induced expression of the pro-inflammatory proteins vascular cell adhesion molecule-1 (VCAM-1), cycloxygenase-2 (COX-2), and PCB77-induced expression and activity of the aryl hydrocarbon receptor (AHR) responsive cytochrome P450 1A1 (CYP1A1). Furthermore, basal AHR expression was downregulated by fenofibrate and WY14643. We also investigated the possible interactions between PCBs, and basal PPAR activity and protein expression. Treatment with PCB77 significantly reduced basal mRNA expression of PPARalpha and the PPAR responsive gene CYP4A1, as well as PPARalpha protein expression. Also, PCB77 exposure caused a significant decrease in basal PPAR-dependent reporter gene expression in MCF-7 cells. Overall, these findings suggest that PPARalpha agonists can reduce PCB77 induction of endothelial cell activation by inhibition of the AHR pathway, and that coplanar PCB induced pro-inflammatory effects could be mediated, in part, by inhibition of PPARalpha expression and function.


Subject(s)
Coronary Artery Disease/chemically induced , Coronary Artery Disease/pathology , Endothelium, Vascular/drug effects , Environmental Pollutants/antagonists & inhibitors , Environmental Pollutants/toxicity , Inflammation/chemically induced , Inflammation/pathology , PPAR alpha/drug effects , Polychlorinated Biphenyls/antagonists & inhibitors , Polychlorinated Biphenyls/toxicity , Animals , Cells, Cultured , Cyclooxygenase 2/biosynthesis , Cytochrome P-450 CYP1A1/antagonists & inhibitors , Cytochrome P-450 CYP1A1/metabolism , Endothelial Cells/drug effects , Endothelium, Vascular/pathology , Genes, Reporter/drug effects , Ligands , PPAR alpha/agonists , PPAR alpha/antagonists & inhibitors , Receptors, Aryl Hydrocarbon/biosynthesis , Receptors, Aryl Hydrocarbon/drug effects , Receptors, Aryl Hydrocarbon/physiology , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/physiology , Swine , Vascular Cell Adhesion Molecule-1/biosynthesis
7.
Cancer Res ; 67(16): 7765-72, 2007 Aug 15.
Article in English | MEDLINE | ID: mdl-17699781

ABSTRACT

Here, we show that the platelet-derived growth factor receptor (PDGFR) regulates myeloid and monocytic differentiation of HL-60 myeloblastic leukemia cells in response to retinoic acid (RA) and vitamin D3 (D3), respectively. Both RA and D3 decreased the expression of PDGFR-alpha and PDGFR-beta throughout differentiation. When cells were treated with the PDGFR inhibitor AG1296 in addition to RA or D3, signs of terminal differentiation such as inducible oxidative metabolism and cell substrate adhesion were enhanced. These changes were accompanied by an increased extracellular signal-regulated kinase 1/2 activation. AG1296 also resulted in elevated expression of differentiation markers CD11b and CD66c when administered with RA or D3. Interestingly, other markers did not follow the same pattern. Cells receiving AG1296 in addition to RA or D3 showed decreased G1-G0 arrest and CD14, CD38, and CD89 expression. We thus provide evidence that certain sets of differentiation markers can be enhanced, whereas others can be inhibited by the PDGFR pathway. In addition, we found calcium levels to be decreased by RA and D3 but increased when AG1296 was given in addition to RA or D3, suggesting that calcium levels decrease during myeloid or monocytic differentiation, and elevated calcium levels can disturb the expression of certain differentiation markers.


Subject(s)
Monocytes/pathology , Myeloid Cells/pathology , Receptors, Platelet-Derived Growth Factor/metabolism , ADP-ribosyl Cyclase 1/biosynthesis , Antigens, CD/biosynthesis , CD11b Antigen/biosynthesis , Calcium/metabolism , Cell Adhesion/drug effects , Cell Adhesion Molecules/biosynthesis , Cell Differentiation , Cholecalciferol/pharmacology , GPI-Linked Proteins , HL-60 Cells , Humans , Lipopolysaccharide Receptors/biosynthesis , Membrane Glycoproteins/biosynthesis , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Monocytes/metabolism , Myeloid Cells/metabolism , Phosphorylation , Receptors, Fc/biosynthesis , Receptors, Platelet-Derived Growth Factor/antagonists & inhibitors , Receptors, Platelet-Derived Growth Factor/biosynthesis , Resting Phase, Cell Cycle/drug effects , Tretinoin/pharmacology , Tyrphostins/pharmacology , Ubiquitin/metabolism
8.
Cancer Res ; 66(18): 9083-9, 2006 Sep 15.
Article in English | MEDLINE | ID: mdl-16982750

ABSTRACT

The role of Janus-activated kinase (JAK) signaling in cell cycle transit and maintenance of genomic stability was determined in HL-60 myeloblastic leukemia cells. Inhibition of JAKs, all JAKs (JAK1, JAK2, JAK3, and tyrosine kinase 2), JAK2, or JAK3, caused a significant reduction in cell growth with a major G2-M arrest evident 24 hours after treatment. Targeting all JAKs also caused endoreduplication 48 and 72 hours after treatment. We discovered mitotic cells in both G2 (4N DNA) and G4 (8N DNA) subpopulations of cells treated with an inhibitor of all JAKs as detected by phosphorylated histone H3 expression. Treatment with inhibitors of just JAK2 or JAK3 drastically reduced such mitotic cells. We observed a complete blockage of IFN-gamma and interleukin-6-induced signal transducer and activator of transcription (STAT)-1 and STAT-3 response when all JAKs were inhibited. At the same time, we found baseline phosphorylated extracellular signal-regulated kinase (ERK) 1/2 to be elevated by JAK inhibition, particularly when all JAKs were inhibited. The G2-M arrest and endoreduplication induced by JAK inhibitors were reduced in cells pretreated with PD98059 to inhibit ERK. PD98059 also increased back the expression of the MAD2 cell cycle checkpoint protein that was down-regulated during "all JAKs inhibitor"-mediated endoreduplication. These data suggest that JAK signaling is needed for G2-M transit with inhibition of ERK.


Subject(s)
Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Protein-Tyrosine Kinases/antagonists & inhibitors , Calcium-Binding Proteins/biosynthesis , Cell Cycle Proteins/biosynthesis , Cell Division/drug effects , Cell Growth Processes/drug effects , Cell Growth Processes/physiology , Flavonoids/pharmacology , G2 Phase/drug effects , HL-60 Cells , Humans , Janus Kinase 1/antagonists & inhibitors , Janus Kinase 1/metabolism , Janus Kinase 2/antagonists & inhibitors , Janus Kinase 2/metabolism , Janus Kinase 3/antagonists & inhibitors , Janus Kinase 3/metabolism , Mad2 Proteins , Mitosis/drug effects , Mitosis/physiology , Phosphorylation , Protein Kinase Inhibitors/pharmacology , Protein-Tyrosine Kinases/metabolism , Repressor Proteins/biosynthesis , STAT1 Transcription Factor/metabolism , STAT3 Transcription Factor/metabolism , TYK2 Kinase/antagonists & inhibitors , TYK2 Kinase/metabolism
9.
J Nutr ; 135(9): 2114-8, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16140885

ABSTRACT

Low zinc concentration can be associated with an increased risk of cardiovascular diseases. In the current study, we hypothesize that zinc deficiency can increase and zinc supplementation can decrease proatherosclerotic events in LDL receptor knock-out (LDL-R-/-) mice fed a moderate-fat diet. Mice were fed either a zinc-deficient (0 micromol Zn/g), a control (0.45 micromol Zn/g), or a zinc-supplemented (1.529 micromol Zn/g) diet for 4 wk. Mice fed the zinc-deficient diet had significantly increased concentrations of cholesterol and triacylglycerides in the VLDL and HDL fractions. Zinc supplementation decreased these lipid variables compared with control mice. We detected significantly higher concentrations of glutathione reductase mRNA in the thoracic aortae of zinc-deficient mice. Furthermore, inflammatory markers, such as nuclear factor-kappaB and vascular cell adhesion molecule-1, were significantly increased in zinc-deficient mice compared with mice of the control or supplemented groups. In addition, zinc deficiency significantly reduced the DNA binding activity of peroxisome proliferator activate receptors (PPARs) in liver extracts. Interestingly, mRNA expression levels of PPARgamma were significantly increased in thoracic aortae of zinc-deficient mice, indicating an adaptation process to decreased PPAR signaling. These data provide in vivo evidence of zinc deficiency inducing proinflammatory events in an atherogenic mouse model. These data also suggest that adequate zinc may be a critical component in protective PPAR signaling during atherosclerosis.


Subject(s)
Atherosclerosis/metabolism , Biomarkers/metabolism , Lipids/blood , Receptors, LDL/deficiency , Zinc/deficiency , Animals , Body Weight , Glutathione Reductase/genetics , Liver/metabolism , Mice , Mice, Knockout , Osmolar Concentration , PPAR gamma/genetics , RNA, Messenger/metabolism , Transcription Factors/metabolism , Vascular Cell Adhesion Molecule-1/genetics , Vascular Cell Adhesion Molecule-1/metabolism , Zinc/metabolism
10.
Cardiovasc Toxicol ; 5(2): 153-60, 2005.
Article in English | MEDLINE | ID: mdl-16046791

ABSTRACT

We hypothesize that nutrition can modulate the toxicity of environmental pollutants and thus modulate health and disease outcome associated with chemical insult. There is now increasing evidence that exposure to persistent organic pollutants, such as PCBs, can contribute to the development of inflammatory diseases such as atherosclerosis. Activation, chronic inflammation, and dysfunction of the vascular endothelium are critical events in the initiation and acceleration of atherosclerotic lesion formation. Our studies indicate that an increase in cellular oxidative stress and an imbalance in antioxidant status are critical events in PCB-mediated induction of inflammatory genes and endothelial cell dysfunction. Furthermore, we have found that specific dietary fats can further compromise endothelial dysfunction induced by selected PCBs and that antioxidant nutrients (such as vitamin E and dietary flavonoids) can protect against endothelial cell damage mediated by these persistent organic pollutants. Our recent data suggest that membrane lipid rafts such as caveolae may play a major role in the regulation of PCB-induced inflammatory signaling in endothelial cells. In addition, PCB- and lipid-induced inflammation can be down-regulated by ligands of anti-atherogenic peroxisome proliferator-activated receptors (PPARs). We hypothesize that PCBs contribute to an endothelial inflammatory response in part by down-regulating PPAR signaling. Our data so far support our hypothesis that antioxidant nutrients and related bioactive compounds common in fruits and vegetables protect against environmental toxic insult to the vascular endothelium by down-regulation of signaling pathways involved in inflammatory responses and atherosclerosis. Even though the concept that nutrition may modify or ameliorate the toxicity of environmental chemicals is provocative and warrants further study, the implications for human health could be significant. More research is needed to understand observed interactions of PCB toxicity with nutritional interventions.


Subject(s)
Arteriosclerosis/prevention & control , Environmental Pollutants/antagonists & inhibitors , Environmental Pollutants/toxicity , Nutritional Physiological Phenomena , Animals , Antioxidants/pharmacology , Arteriosclerosis/chemically induced , Caveolae/drug effects , Diet , Dietary Fats/pharmacology , Endothelial Cells/drug effects , Humans , Peroxisome Proliferator-Activated Receptors/genetics , Peroxisome Proliferator-Activated Receptors/physiology , Polychlorinated Biphenyls/toxicity
11.
Environ Health Perspect ; 113(1): 83-7, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15626652

ABSTRACT

There is evidence that dietary fat can modify the cytotoxicity of polychlorinated biphenyls (PCBs) and that coplanar PCBs can induce inflammatory processes critical in the pathology of vascular diseases. To test the hypothesis that the interaction of PCBs with dietary fat is dependent on the type of fat, low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice were fed diets enriched with either olive oil or corn oil for 4 weeks. Half of the animals from each group were injected with PCB-77. Vascular cell adhesion molecule-1 (VCAM-1) expression in aortic arches was nondetectable in the olive-oil-fed mice but was highly expressed in the presence of PCB-77. PCB treatment increased liver neutral lipids and decreased serum fatty acid levels only in mice fed the corn-oil-enriched diet. PCB treatment increased mRNA expression of genes involved in inflammation, apoptosis, and oxidative stress in all mice. Upon PCB treatment, mice in both olive- and corn-oil-diet groups showed induction of genes involved in fatty acid degradation but with up-regulation of different key enzymes. Genes involved in fatty acid synthesis were reduced only upon PCB treatment in corn-oil-fed mice, whereas lipid transport/export genes were altered in olive-oil-fed mice. These data suggest that dietary fat can modify changes in lipid metabolism induced by PCBs in serum and tissues. These findings have implications for understanding the interactions of nutrients with environmental contaminants on the pathology of inflammatory diseases such as atherosclerosis.


Subject(s)
Dietary Fats/pharmacology , Environmental Pollutants/pharmacology , Environmental Pollutants/poisoning , Polychlorinated Biphenyls/pharmacology , Polychlorinated Biphenyls/poisoning , Receptors, LDL/drug effects , Receptors, LDL/physiology , Animals , Diet , Drug Interactions , Mice
12.
J Nutr ; 134(7): 1711-5, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15226458

ABSTRACT

Zinc is an essential structural component of various proteins and is crucial for the integrity of the vascular endothelium. The present study focused on the effect of zinc deficiency on the anti-inflammatory properties of peroxisome proliferator activated receptor (PPAR) alpha and gamma agonists. Porcine pulmonary-arterial endothelial cells were deprived from zinc by chelator N,N,N',N'-tetrakis (2-pyridylmethyl)ethylene diamine. Cells were exposed to TNF-alpha for 2 h following pretreament with the PPARalpha agonists fenofibrate or ciprofibrate or the PPARgamma agonists thiazolidinedione or troglitazone. The inflammatory response was tested by measuring nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1) binding activities as well as by measuring mRNA expression levels of inflammatory genes, such as vascular cell adhesion molecule-1 (VCAM-1) and IL-6. All PPAR agonists tested lost their potency to downregulate the TNF-alpha-induced inflammatory response in zinc-deficient cells. However, if zinc was added back, all PPAR agonists significantly downregulated the TNF-alpha-mediated induction of inflammatory transcription factors NF-kappaB and AP-1 and significantly reduced the expression of their target genes, VCAM-1 and IL-6. We therefore hypothesize that zinc is required for the PPARalpha and -gamma DNA binding activity. Indeed, zinc deficiency significantly reduced the agonist-induced binding activity of PPARalpha and -gamma to the PPAR response element. Our data demonstrate the importance of zinc in PPAR signaling and the requirement of zinc for the anti-inflammatory properties of PPARalpha and -gamma agonists.


Subject(s)
Endothelium, Vascular/drug effects , Inflammation/prevention & control , Receptors, Cytoplasmic and Nuclear/drug effects , Transcription Factors/drug effects , Zinc/pharmacology , Animals , Cells, Cultured , Endothelium, Vascular/metabolism , Interleukin-6/metabolism , Receptors, Cytoplasmic and Nuclear/agonists , Receptors, Cytoplasmic and Nuclear/physiology , Swine , Transcription Factors/agonists , Transcription Factors/physiology , Vascular Cell Adhesion Molecule-1/metabolism , Zinc/deficiency
13.
J Nutr ; 134(4): 771-5, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15051824

ABSTRACT

Consumption of plant phenolics, such as quercetin, may be associated with decreased risk of cardiovascular disease by stabilizing and protecting vascular endothelial cells against oxidative and proinflammatory insults. The present study focused on the effect of quercetin on linoleic acid-induced oxidative stress and the inflammatory pathways of nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1). Because the transcription factor peroxisome proliferator activated receptor gamma (PPARgamma) was reported to downregulate inflammatory pathways, we further investigated the effect of quercetin on PPARgamma. Porcine pulmonary-arterial endothelial cells were activated with linoleic acid in the presence or absence of quercetin. Oxidative stress was markedly induced by endothelial cell exposure to linoleic acid and diminished by treatment with quercetin as measured via the oxidation of 2',7'-dichlorofluorescin. Quercetin reduced linoleic acid-mediated binding activity of NF-kappaB and AP-1 and mRNA levels of inflammatory genes such as interleukin-6 (IL-6) and vascular cell adhesion molecule-1 (VCAM-1). Cotreatment of linoleic acid plus quercetin or vitamin E also decreased linoleic acid-induced binding activity of PPARgamma. These data suggest that quercetin has potent antioxidative and anti-inflammatory properties and protects endothelial cells against linoleic acid-mediated cell dysfunction.


Subject(s)
Antioxidants/pharmacology , Endothelial Cells/drug effects , Endothelial Cells/physiology , Linoleic Acid/pharmacology , Quercetin/pharmacology , Animals , Interleukin-6/genetics , NF-kappa B/metabolism , Oxidation-Reduction , Oxidative Stress/drug effects , RNA, Messenger/analysis , Receptors, Cytoplasmic and Nuclear/metabolism , Swine , Transcription Factor AP-1/metabolism , Transcription Factors/metabolism , Vascular Cell Adhesion Molecule-1/genetics , Vitamin E/pharmacology
14.
J Nutr ; 133(10): 3058-64, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14519784

ABSTRACT

Dietary zinc has potent antioxidant and anti-inflammatory properties and is a critical component of peroxisome proliferator-activated receptor (PPAR) gene expression and regulation. To assess the protective mechanisms of PPARgamma in endothelial cell dysfunction and the role of zinc in the modulation of PPARgamma signaling, cultured porcine pulmonary artery endothelial cells were exposed to the membrane-permeable zinc chelator N,N,N'N'-tetrakis (2-pyridylmethyl)-ethylene diamine (TPEN), thiazolidinedione (TZD; PPARgamma agonist) or bisphenol A diglycidyl ether (BADGE; PPARgamma antagonist). Subsequently, endothelial cells were activated by treatment with linoleic acid (90 micro mol/L) for 6 h. Zinc chelation by TPEN increased the DNA binding activity of nuclear factor (NF)-kappaB and activator protein (AP)-1, decreased PPARgamma expression and activation as well as up-regulated interleukin (IL)-6 expression and production. These effects were fully reversed by zinc supplementation. In addition, exposure to TZD down-regulated linoleic acid-induced DNA binding activity of NF-kappaB and AP-1, whereas BADGE further induced activation of these oxidative stress-sensitive transcription factors. Most importantly, the TZD-mediated down-regulation of NF-kappaB and AP-1 and reduced inflammatory response were impaired during zinc chelation. These data suggest that zinc plays a critical role in PPARgamma signaling in linoleic acid-induced endothelial cell activation and indicate that PPARgamma signaling is impaired during zinc deficiency.


Subject(s)
Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Receptors, Cytoplasmic and Nuclear/metabolism , Signal Transduction/drug effects , Transcription Factors/metabolism , Zinc/pharmacology , Animals , Benzhydryl Compounds , Cells, Cultured , Chelating Agents/pharmacology , DNA/metabolism , Diet , Electrophoretic Mobility Shift Assay , Epoxy Compounds , Ethylenediamines/pharmacology , Interleukin-6/metabolism , Linoleic Acid/pharmacology , NF-kappa B/metabolism , Pulmonary Artery , Receptors, Cytoplasmic and Nuclear/agonists , Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors , Swine , Thiazolidinediones/pharmacology , Transcription Factor AP-1/metabolism , Transcription Factors/agonists , Transcription Factors/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...